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ABSTRACT 
Background and aims: Smoking cessation medications are effective but often underutilised 
because of costs and side effects. Cytisine is a plant-based smoking cessation medication 
with over 50 years of use in Central and Eastern Europe. While cytisine has been found to 
be well-tolerated and more effective than nicotine replacement therapy, direct comparison 
with varenicline have not been conducted. This study evaluates the effectiveness, safety and 
cost-effectiveness of cytisine compared with varenicline. Design: Two arm, parallel group, 
randomised, non-inferiority trial, with allocation concealment and blinded outcome 
assessment. Setting: Australian population-based study. Participants: Adult daily smokers 
(N=1266) interested in quitting will be recruited through advertisements and Quitline 
telephone-based cessation support services. Intervention and comparator: Eligible 
participants will be randomised (1:1 ratio) to receive either cytisine capsules (25-day supply) 
or varenicline tablets (12-week supply), prescribed in accordance with the manufacturer’s 
recommended dosing regimen. The medication will be mailed to each participant’s 
nominated residential address. All participants will also be offered standard Quitline 
behavioural support (up to six 10-12 minute sessions). Measurements: Assessments will be 
undertaken by telephone at baseline, 4- and 7-months post-randomisation. Participants will 
also be contacted twice (two and four weeks post-randomisation) to ascertain adverse 
events, treatment adherence and smoking status.  The primary outcome will be self-reported 
6-month continuous abstinence from smoking, verified by carbon monoxide at 7-month 
follow-up. We will also evaluate the relative safety and cost-effectiveness of cytisine 
compared with varenicline. Secondary outcomes will include self-reported continuous and 7-
day point prevalence abstinence and cigarette consumption at each follow-up interview.  
Comments: If cytisine is as effective as varenicline, its lower cost and natural plant-based 
composition may make it an acceptable and affordable smoking cessation medication that 
could save millions of lives worldwide.  
Keywords Cytisine, varenicline, smoking cessation, tobacco, randomised controlled trial 
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INTRODUCTION  
Tobacco smoking continues to be a leading cause of preventable morbidity and mortality 
worldwide(1, 2). Helping smokers to quit is therefore a priority. Bupropion, nicotine 
replacement therapy (NRT) and varenicline improve long-term abstinence rates when used 
in quit attempts(3). Bupropion and NRT are equally effective and varenicline is superior to 
both bupropion and NRT (when used singly). On current evidence varenicline is the most 
effective sole pharmacotherapy for smoking cessation(3). The safety of varenicline is also 
established. A recent large-scale (n=8144) study established its safety in smokers with and 
without psychiatric disorders (4).    
Smoking cessation interventions can be highly cost-effective, but some medications come at 
a substantial cost to the health care sector and consumers and so may divert significant 
resources away from other interventions or be unaffordable(5). For example, in 2017, 
Australia’s Pharmaceutical Benefit Scheme spent more than $30 million subsidising 
varenicline(6). A wider choice of more cost-effective methods is needed to reduce the costs 
associated with smoking cessation and the global smoking burden in low- and middle-
income countries (LMICs), where smoking cessation medications are unavailable, or cost 
prohibitive(7, 8).  
Cytisine is a plant-based alkaloid found in members of the Leguminosae family (e.g., Cytisus 
laburnum)(9). Like varenicline, cytisine is a partial agonist of nicotinic acetylcholine receptors 
(nAChRs), binding with high affinity to the α4β2 subtype, which is central to the effect of 
nicotine on the reward pathway. Cytisine acts by reducing the rewarding effect of nicotine 
and attenuating nicotine withdrawal symptoms(10, 11).  
Cytisine was first used in Bulgaria as a smoking cessation aid in the early 1960s providing 
inexpensive and effective cessation support to millions of smokers in Central and Eastern 
Europe(10). Modelling suggests cytisine may produce substantial cost savings for the global 
healthcare system if used instead of common smoking cessation pharmacotherapies(12). A 
review concluded that cytisine is the most promising future smoking cessation treatment(13).  
Cytisine is: (i) inexpensive to produce(9, 14) and currently priced at a half to a twentieth of 
other cessation medications(9); (ii)  well-tolerated by smokers(15); (iii) requires a shorter 
treatment period (i.e., 25 days) than the 56 to 84 days for NRT, bupropion and 
varenicline(15); and (iv) plant-based which may be attractive for smokers who prefer ‘natural’ 
medicines(16).  
Nine placebo-controlled and seven uncontrolled studies have demonstrated the safety and 
efficacy of cytisine(15, 17). Most of these studies did not meet contemporary standards and 
were published in non-English language Journals and hence cytisine did not receive 
considerable interest outside of Europe until a review was published by Etter et al in 2006 
(14, 17, 18). One high-quality pragmatic non-inferiority trial (n=1310) found that cytisine was 
superior to NRT in improving self-reported continuous abstinence rates at one week, and 
one, two and six months when both groups received minimal behavioural support(19). 
Although the self-reported adverse event (AE) rates were higher in the cytisine group than in 
the NRT group (31% and 20% respectively), the majority of events were mild to moderate in 
severity and self-limited. The most frequent AEs in the cytisine arm were nausea/vomiting 
and sleep disorders (4.6% and 4.3% of the total sample that received cytisine respectively). 
Among smokers who received cytisine and reported an AE, over 82% would recommend 
cytisine to a smoker who wanted to quit. Moreover, West et al in 2011 reported that the 
latest Periodic Safety Update provided to European authorities (based on seven million 
cytisine users) did not identify any safety concerns(20).  
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Cytisine may be as effective, cheaper and therefore more cost-effective than varenicline(21). 
However, there are no clinical trials comparing cytisine with varenicline in the same 
population. The primary objective of this study is to evaluate the effectiveness of cytisine 
compared to varenicline on six-month continuous abstinence verified at seven-month follow-
up. We will also compare the relative safety and the cost-effectiveness of cytisine to 
varenicline. We hypothesise that cytisine will be at least as effective and more cost-effective 
than varenicline.  
METHODS 
Design 
Parallel group, non-inferiority, randomised controlled cost-effectiveness trial .   
Setting 
This is a population-based study undertaken in New South Wales, Australia. Screening and 
consenting processes will be completed by staff at the Trial Coordinating Centre (TCC) 
located at the University of New South Wales (UNSW), National Drug and Alcohol Research 
Centre (NDARC), Sydney, Australia. Baseline and follow-up computer assisted telephone 
interviews (CATIs) will be completed by an independent Contract Research Organisation 
(CRO) – The Social Research Centre (SRC) located in Melbourne, Australia.  
Study criteria  
Inclusion criteria  
At least 18 years of age; current daily smoker (smoking at least one cigarette per day at the 
time of screening); willing to make a quit attempt using the medication provided (cytisine or 
varenicline); able to provide verbal informed consent; have access to a telephone; and 
willing to complete baseline and follow-up telephone interviews.  
Exclusion criteria  
Pregnant, breastfeeding or planning to become pregnant in the next 7-months; currently 
using smoking cessation medications; participating in another smoking cessation study; 
having known hypersensitivity to the active substance or to any of the excipients; 
hospitalised for any of the following medical conditions in the previous 3-months: arrhythmia, 
heart attack, stroke, severe angina; or diagnosed with pheochromocytoma or 
hyperthyroidism.  
Participant recruitment   
Participants will be recruited from two recruitment streams.  
Quitline 
Trained Quitline counsellors will briefly inform their clients about the study (i.e., a study that 
provides free support to smokers to quit) and ask if they are interested in hearing more about 
the study. Those interested will have their contact details passed onto the research team at 
the TCC. 
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Advertisements  
We will advertise using: i) print (i.e., newspaper, letterbox flyer drops, posters and flyers 
displayed at primary care centres, pharmacies, notice/bill boards, and health and 
government organisations); ii) radio; and iii) digital media (i.e., Facebook and Google Ads, 
plus other online advertisements). The advertisements will include a toll-free study number 
for interested smokers.   
Recruitment procedures  
All potential participants expressing interest in the study will be asked to choose their 
preferred method of receiving the participant information statement (i.e., via either hard copy 
mail or email or link to study website). The TCC will then contact potential participants, 
reiterate the study details, check eligibility including current medical conditions and 
medications, review self-reported medical history, and if eligible, obtain verbal informed 
consent. The consent will include a permission to audiotape the screening interview, 
providing access to screening files to a study clinician (SC) and permission to transfer 
contact details between various stakeholders involved in the study (see Figure 1). All 
randomised participants will also receive a consent form for releasing their Medicare and 
Pharmaceutical Benefits Scheme (PBS) claims information, though it is not a requirement for 
study participation.  
The product monographs for cytisine and varenicline advise caution for the following 
conditions: psychiatric illness, ischemic heart disease, heart failure, cerebrovascular 
diseases, obliterating arterial diseases, diabetes mellitus (caution indicated for those who 
are on insulin therapy), renal and hepatic insufficiency, hypertension, active 
gastroesophageal reflux disorder or peptic ulcer disorder and people with history of seizures. 
If a cautionary condition is self-reported, the SC will consult the participant via phone before 
enrolling them in the study. If the current status of the condition is uncertain or further 
information is required, the participant may be asked for a letter of clearance from their usual 
doctor.  
Participants’ mental health status will be assessed using the short and validated Kessler 
Psychological Distress Scale (K6)(22). All participants with a score of 13 or above (probable 
serious mental illness) will be referred to the SC for further evaluation before enrolment. 
Suicidal ideation will be assessed using adapted items from the Australian National Survey 
of Mental Health and Wellbeing (Did the below experience ever happen to you? The 
experience is “You seriously thought about committing suicide” [A serious thought is having 
suicidal thoughts for a few days or making plans for it or attempting to do it. It is not a 
momentary or passing thought at some stage of your life]. If “yes”, did that experience 
happen to you at any time in the past 12 months?). Those who report suicidal thoughts in the 
previous 12-months will be evaluated by the SC.  
The SC will screen and assess all consented participants’ files and provide final sign off, 
after which participants are referred to the CRO for a baseline CATI. Details of consented 
participants will be sent to the CRO using a secured file transfer system (ShareFile®). 
Further information is provided in the study flow diagram (See Figure 1).  
Randomisation: allocation concealment and sequence generation 
Participants will be randomised to treatment after completion of the baseline CATI. The data 
collection system at the CRO (UNICOM® Intelligence) will assign a unique randomisation 
number to all participants using a pre-generated randomisation list embedded in the system. 
The allocations will be undertaken using the permuted block design (with unequal block 
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sizes of 12 and 16)(23). After baseline interview, the system will randomise participants to 
either of the treatment arms in a 1:1 ratio. Only the independent statistician will have access 
to the pre-generated randomisation list.   
Blinding 
All outcome assessments will be conducted by the independent CRO. The interviewers who 
conduct outcome assessments will use the unique study ID (i.e., randomisation number) and 
not know the person’s treatment allocation. To prevent participants revealing their treatment 
allocation to the interviewer, the person conducting follow-up assessments will use a 
protocol that instructs participants at the outset of each interview not to discuss treatment 
allocations with the interviewer. Because of differences in dosage form, dosing regimen, 
treatment duration and quit day, participants and research staff (who perform day-to-day 
activities and conduct check-in calls) cannot be blinded.    
Study treatments 
Participants will be randomised to receive either cytisine or varenicline. The CRO will provide 
the information on the allocated medication and designated quit date after randomisation. 
Participants will be advised to follow the dosing regimen as recommended by the 
manufacturer (See Supplementary Table 1 and 2). Study medications and materials will be 
delivered to participants’ residential address by mail from a central pharmacy– ePharmacy 
located in Brisbane, Australia. A trained study pharmacist at the central pharmacy will re-
evaluate participants’ medical and medication history before dispensing the study 
medications.  
Intervention group  
Participants in the intervention group will receive the standard 25-day supply of 1.5 mg 
cytisine micronised capsules (Desmoxan brand). The designated quit date will be on the fifth 
day from the start of the treatment. The medication will be sent in one shipment.  
Comparator group  
Participants in the comparator group will receive the standard 12-week supply of 0.5 mg/1.0 
mg varenicline tablets (Champix brand). The initiation pack (4-week supply) will be 
dispatched immediately after randomisation. The continuation pack (8-week supply) will be 
dispatched to those who have started the initiation pack (as confirmed by phone) and are 
interested to continue treatment. The designated quit date will be on the eighth day from the 
start of the treatment. 
Quitline support 
All participants will be offered standard Quitline behavioural support. This includes a free 
call-back service with scheduled additional support calls (six 10-12 minutes sessions) from a 
counsellor, and a quit kit containing self-help quitting guides(24). TCC staff will complete an 
online referral form on behalf of participants who gave consent to be referred to Quitline. 
Consent to receive Quitline support is not required for study enrolment and those recruited 
via Quitline will not be referred.    
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DATA COLLECTION AND MEASUREMENTS  
Follow-up 
The independent CRO will complete all assessments at baseline, and at 4- and 7-month 
post-randomisation (See Figure 2) using a structured CATI program. Participants will be 
reimbursed $40 for completing each interview.  
Check-in calls  
All participants will receive two check-in calls (See Figure 2). The non-adherence and 
adverse side effects usually occur during the initial phase of treatment and hence we will 
conduct 2 check-in calls during the first month of treatment. This is the first study using 
check-in calls to capture a comprehensive data on cytisine’s safety, and more than 2 check-
in calls are not feasible due to study budget constraints. These calls will be conducted by 
trained research staff at the TCC. The study clinician will be notified of any unusual or 
serious health problems identified during these calls. 
Treatment adherence 
Participants will receive a clear instruction on the dosage regime immediately after 
randomisation by the CRO. The participants will also receive consumer medicine information 
and a leaflet detailing dosage regimen, designated quit day, common side effects and study 
contact details along with the medication pack. The treatment adherence will be monitored 
during the check-in calls and those who are not adherent will be encouraged to use the 
medication as per the schedule. Self-reported treatment adherence will be assessed at 
follow-up 1 and 2.  
Measurements  
Primary outcome 
The primary outcome will be biochemically verified 6-month continuous abstinence at 7-
month post-randomisation. Six months continuous abstinence will be defined by self-report 
as not having smoked more than five cigarettes for the entire 6-month period preceding the 
7-month follow-up(25). Only participants who self-report continuous abstinence at 7-month 
post-randomisation will be biochemically verified. Participants meeting this self-reported 
criterion will be asked to perform a Carbon Monoxide (CO) breath test. Participants will be 
asked to either visit the TCC or have a trained researcher attend their home to perform this 
test. Participants will be reimbursed $40 for test completion.  
The CO level in the exhaled air will be measured using a hand-held Micro+ Smokerlyzer 
(Bedfont Scientific Ltd, Maidstone, Kent, England). The exhaled CO level is the cheapest, 
easiest and most simple method of verifying tobacco use with around 90% sensitivity and 
specificity(26). A participant with an exhaled CO level of ≤9 ppm will be considered 
abstinent(26). Participants who self-report abstinence but are unable or unwilling to complete 
CO test will be classified as smoking (treatment failure) for the primary outcome.     
Secondary outcome measures   
The secondary outcome measures are: 1) Participant self-reported continuous abstinence at 
each follow-up interview (3-month continuous abstinence at 4-month follow-up and 6-month 
continuous abstinence at 7-month follow-up; 2) Self-reported 7-day point prevalence 
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abstinence (defined as prevalence of abstinence during seven consecutive days immediately 
preceding the follow-up) at 4- and 7-month follow-ups; and 3) Self-reported cigarette 
consumption at each follow-up.  
Safety monitoring 
Participants will complete two check-in calls and two follow-up interviews during which data 
will be collected on the type, severity, causality, action taken, and outcome of self-reported 
AEs will be collected. A toll-free number will be available for participants to self-report any 
AE and seek advice from staff at the TCC.  
An AE will include any illness, sign, symptom, or clinically significant abnormality that has 
appeared or worsened during the clinical trial, regardless of its causal relationship to the 
study medications. All AEs will be carefully evaluated and summarised using MedDRA 
(Medical Dictionary for Regulatory Activities) coding. The severity will be assessed using 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 general guidelines 
(i.e. grade 1 – Mild AE; grade 2 – moderate AE; grade 3 – severe AE; grade 4 – life-
threatening or disabling AE; and grade 5 – death related to AE). Causality will be assessed 
using the World Health Organization (WHO) criteria for causality assessment (certain, 
probable/likely, possible, unlikely, conditional/unclassified and unassessable/unclassifiable). 
There are no formal stopping rules set for this study, but an independent Data Safety 
Monitoring Board (DSMB) will evaluate the safety data emerging from the study at least 
biannually and make recommendations on whether to continue the trial without changes, 
continue with changes or terminate the trial early.  
Other measurements  
A number of potential baseline covariates, mediating factors and other outcome variables 
will also be collected at baseline and at each follow-up. Table 1 lists the data collection 
schedule for all variables (primary, secondary, covariates, mediating factors and exploratory 
outcomes).  
Sample size   
A sample size of 1266 (633 per group) will confer 90% power at the one-sided significance 
level of 0.025 to detect a non-inferiority margin of 5% between the two groups at 7-month 
follow-up. The 6-month self-reported continuous abstinence rate was 22% in the cytisine 
group in a recent pragmatic trial in a similar group of smokers, i.e. motivated Quitline 
callers(19). For the power calculation, we have assumed a conservative 19% biochemically 
verified quit rate in the cytisine group. A Cochrane review identified continuous abstinence 
rates (≥6 months) for varenicline as approximately 27% compared to placebo(27). However, 
pragmatic evaluations have identified much lower rates of smoking cessation with 
varenicline and heterogeneity according to clinical practice and the population treated(28). 
For example, a recent study (n= 3,116) assessing Quitline enrolees using varenicline 
identified a 17% continuous cessation rate at 6-months(29). A recent modelling study 
estimated that cytisine will be more clinically effective than varenicline(21). For the power 
calculation, we have assumed a 17% quit rate in the comparator arm given that this is a 
pragmatic population-based study.  
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Data management  
The data at the TCC will be captured in a specially designed Microsoft SQL database. The 
clinician and central pharmacy will have restricted access to the SQL database using a 
secured gateway GlobalProtect. The data collected at the CRO will be stored in an electronic 
database, UNICOM® Intelligence. An automatic file transfer system will be designed by 
connecting MS SQL database with CRO and central pharmacy databases using a secured 
file exchange portal, ShareFile®. This will mediate the automatic file transfer between 
different stakeholders. The data will be encrypted in transit and in storage.   
Data analysis  
Baseline characteristics  
Baseline characteristics of the cytisine and varenicline group will be presented using 
frequency and percentages for categorical variables and means/standard deviations for 
continuous measures. 
Treatment effects  
The analysis plan will be pre-specified. The primary analysis will compare the quit rates 
between the two groups. Regression analysis will be used to compare quit rates between the 
two treatment groups (both adjusted and unadjusted). Non-inferiority will be evaluated by 
observing whether the lower bound of the 95% confidence interval for the risk difference in 
quit rate between cytisine and varenicline is above the non-inferiority margin (-5%).    
The primary analysis will be conducted according to intention-to-treat (ITT) principles where 
missing data is treated as smokers. Sensitivity analyses will involve: (1) using multiple 
imputation to account for missing data; (2) excluding participants with missing data; and (3) 
excluding participants with protocol deviations (e.g., not adherent to treatment)(30).  
 
Similar analyses (logistic regression) will be undertaken for the secondary cessation 
outcomes at each follow-up point. There will be an additional combined analysis of all time 
points using a regression model that includes time as a variable and uses a random 
intercept to adjust for correlated observations among individuals over time. The consistency 
of effects among the following subgroups will also be assessed using tests for heterogeneity 
(random-effects model) for primary outcome: age, gender, nicotine dependence (assessed 
using 2-item Heaviness of Smoking Index (HSI) ≥ 4 will be considered as heavy smokers 
and an HSI score of ≤ 3 will be considered as light smokers) and presence of any mental 
health condition. Regression models which adjust for mediating factors such as treatment 
adherence and Quitline use will also be analysed. 
Health economic analyses 
The cost-effectiveness analysis will take a healthcare system perspective. Costs will be 
captured by staff recording the time taken and resources used for assessment, 
administration, drug related costs and treating any complications. Downstream costs 
associated with government subsidised primary care use and other drug use will be 
collected by linkage with Medicare records. First the following within-trial analyses will be 
undertaken. The incremental costs between the cytisine and varenicline groups and 
incremental costs per additional quitter after the 7 months follow-up will be estimated. In 
addition, we will estimate the cost-effectiveness in terms of the incremental cost per 
additional Quality Adjusted Life Year (QALY) - as measured by linear interpolation between 
baseline, follow-up 1 and follow-up 2 QALYs weights as captured by the EQ-5D-5L. 
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Given that the majority of the health benefits and cost savings from quitting are likely to be 
experienced after the trial, the implications for lifetime QALYs and future costs will be 
modelled using the same Markov model structure as in the recent UK HTA report(21) to 
estimate the cost per QALY. Relapse rates and other parameters in the model will be 
estimated using the Household Income Labour Dynamics in Australia (HILDA) survey data, a 
large annual longitudinal cohort which began in 2001. Healthcare cost information will be 
used from the Australian Institute of Health and Welfare (AIHW) to estimate the savings from 
reduced morbidity.  
All analyses will involve probabilistic sensitivity analysis to explore the robustness of the 
conclusions and explore the effects of lower levels of patient adherence. Our estimated 
incremental cost effectiveness ratios will also be compared with those estimated in the 
literature simply based on effectiveness of the intervention, the cost of the intervention and 
other standardised inputs(12). Given that cytisine is not available in Australia, a threshold 
analysis will determine the maximum price the government should be willing to pay. Planned 
sub-group analyses will also be conducted including nicotine dependence (heavy vs light 
smokers), presence of any mental health condition and socioeconomic status.  
Tolerability analysis  
All randomised participants who take at least one dose of cytisine or varenicline will be 
included in the safety analyses. The incidence of AE and frequency of treatment 
discontinuation in both groups will be compared using Chi-square statistic. All suspected 
unexpected serious adverse events reported during the study, and meeting the following 
criteria, will be evaluated promptly and summarised by treatment group: results in death; life-
threatening; requires inpatient hospitalisation or prolongation of existing hospitalization; 
results in persistent or significant disability/incapacity; congenital abnormality/birth defect; or 
an important medical event.  
Ethics 
The trial will be conducted in compliance with the protocol, the principles of Good Clinical 
Practice(31), the National Health and Medical Research Council’s (NHMRC) National 
Statement on Ethical Conduct in Human Research (2007)(32) and the Australian Code for 
the Responsible Conduct of Research (2007)(33). Ethical approval for this study was 
obtained from the University of New South Wales Human Research Ethics Committee. A 
Therapeutic Goods Administration (TGA) notification has been filed as cytisine is not a 
registered product listed on the Australian Register of Therapeutic Goods (ARTG).  
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DISCUSSION   
If cytisine is at least as effective as varenicline it could provide a more affordable cessation 
treatment option for smokers globally that would make substantial savings for health care 
systems and consumers. Although the smoking rate in Australia has been substantially 
reduced over the last two decades, 12.8% of the Australian population still smoke daily(34).  
The shorter treatment regimen and natural composition of cytisine may attract more smokers 
using it as a quitting aid leading to further decrease rates of smoking. The study has the 
potential to inform policy on a treatment that could annually save millions of lives worldwide, 
particularly in LMICs where smoking rates are rising, and existing cessation treatments are 
prohibitively expensive.  
This study has a large sample size and rigorous study design. The telephone-based 
interviews and assessments (telehealth) will improve the recruitment and retention rate as it 
will allow greater flexibility for participants to attend interviews (no travel included)(35). All 
outcome measures at each follow-up interview will be collected by a CRO independent of 
the research team. This is the first clinical trial using cytisine micronised capsules, all the 
previous clinical trials of cytisine used tablets but both contain 1.5 mg of cytisine.    
This study has some limitations. Self-reported data will be used for adherence, safety and all 
other variables except for primary endpoint which will be biochemically verified. Since all 
data are collected remotely by telephone, it is difficult to accurately quantify and grade AEs 
(e.g., laboratory abnormalities, hypertension etc.). However, our trained research staff will 
prompt each participant during each interview to report any changes in their health status 
after commencing the study medication. Detailed information will be obtained to process 
each AE. All data will be collected using a structured CATI. While there are substantial 
differences between both arms – treatment duration (25 days versus 12 weeks), quit day (5th 
day versus 8th day) and dispensing practices (one versus two dispensing) – we are adhering 
to the manufacturers standard treatment regimen which previous clinical trials have found to 
be safe and effective. The existing patent of varenicline will expire in 2020 which may reduce 
its current price.  
Clinical trial registration 
Australian and New Zealand Clinical Trials Registry (ACTRN12616001654448).  
Current status  
The trial started recruitment in January 2018, with recruitment expected to take 18 months. 
Trial findings are expected to be available early 2020.  
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Figure 1: Study Flow Diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: TCC, Trial Coordinating Centre; PIS, Participant Information Sheet; SC, Study 
Clinician; CATI, Computer Assisted Telephone Interview; CRO, Contract Research Organisation  
 
Screening and consenting – TCC (within 1-3 days after sending PIS) 
• Provide further study information & answer any queries  
• Assess eligibility criteria, health conditions and obtain verbal consent 
  
   Authorise enrolment – SC (within 24 hours after screening) 
• SC to screen participant files, check audio recordings, complete teleconsultation (as required), 
and provide final approval for study enrolment   
Baseline CATI – CRO (within 24 hours after clinician endorsement) 
• Complete baseline data collection and randomisation  
• Inform participants of dosage regimen and set quit day  
  
Medication dispensing – Central Pharmacy (within 24 hours after randomisation) 
• Send allocated medication & study information kit which contains detailed written information 
about dosage regimen, quit day, possible withdrawal symptoms and side effects  
Check-in calls – TCC 
• Two check-in calls (at 2 weeks and 4 weeks from randomisation) to check safety, adherence 
and smoking status  
Follow-up CATIs – CRO 
• Follow-up 1: 4 months after randomisation 
• Follow-up 2: 7 months after randomisation  
Biochemical verification – TCC (within 7days after follow-up 2) 
• Carbon Monoxide monitoring for those who self-reported 6-month sustained abstinence at 7-
month follow-up 
Recruitment 
• Advertisements: Interested smokers will call TCC; TCC staff will briefly provide study 
information and send PIS 
• Quitline referrals: Counsellors based at Quitline service will inform callers about the study and 
ask whether they are interested in hearing about a study offering free support to quit; 
Interested smokers will be referred to the TCC and sent PIS 
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Figure 2: Study Plan Schematic 
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Table 1: Summary of assessments 
Variable Scree
ning 
Basel
ine 
Chec
k-in 
calls 
Follow-
up 1 (4 
months) 
Follow-
up 2 (7 
months) 
Age, sex, medical history review and eligibility screening √     
Socio-demographic variables: Country of birth, Aboriginal or 
Torres Strait Islander status, education, employment status, 
marital status, current living arrangement, average annual 
household gross income and possession of any concession 
card.  
 √    
Current medications and medical conditions √  √ √ √ 
Smoking status and number of cigarettes smoked/day  √ √ √ √ 
Pregnancy  √   √ √ 
Access to healthcare services   √    
Smoking habit: Age started; number of cigarettes smoked 
per day; previous quitting experiences and methods used; 
use and experiences with Quitline, NRT, prescription 
medications or electronic cigarettes; perceptions about 
smoking cessation advertisements and taxation; smoking 
cessation care received from health professionals; type of 
cigarettes smoked (e.g. roll-your-own and/or factory-made); 
and money spent on cigarette/week. 
 √    
Nicotine dependence: The nicotine dependence will be 
assessed using 2-item Heaviness of Smoking Index 
(HSI)(36). 
 √  √ √ 
Intention to quit smoking assessed using 4 point criteria (will 
quit in the next 30 days; will quit in the next 6 months, but not 
in the next 30 days; may quit in the future, but not in the next 
6 months; never expect to quit).   
   √ √ 
The physical signs and symptoms associated with 
withdrawal: This will be measured using 12-item Mood and 
Physical Symptoms Scale (MPSS)(37).  
 √ √ √ √ 
Alcohol use and abuse: This will be assessed using 3-item 
Alcohol Use Disorders Identification Test (AUDIT-C)(38). 
 √ √ √ √ 
Cannabis use in the last month 
 √  √ √ 
Health related quality of life: This will be measured using 
EuroQol five dimension questionnaire (EQ-5D-5L)(39). 
 √  √ √ 
Mental distress using 21 item Depression Anxiety Stress 
Scales (DASS)(40).  
 √  √ √ 
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Financial stress using Index of Financial Stress(41).  
 √  √ √ 
Use of other medications and other methods of cessation    √ √ 
Treatment adherence: The self-reported medications use 
(i.e., number of capsules/tablets used)  
  √ √  
Safety   √ √ √ 
Other health resource use    √ √ 
